Tags

Type your tag names separated by a space and hit enter

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Mov Disord. 1995 Nov; 10(6):731-40.MD

Abstract

Dyskinesias occur in the majority of patients with Parkinson's disease chronically treated with L-DOPA and also occur in several nonhuman primate species after 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) and L-DOPA treatment. The common marmoset (Callithrix jacchus) shows parkinsonian motor deficits after MPTP administration, and we now report dyskinesias occurring in this species during chronic L-DOPA exposure. Marmosets rendered chronically parkinsonian after MPTP administration were treated orally with L-DOPA plus carbidopa for 3 weeks. After several days the animals began to display chorea, choreoathetosis, and dystonia. The severity of dyskinesias varied between the animals, with the most severely parkinsonian animals displaying the most dyskinetic movements. Each animal showed an idiosyncratic pattern of dyskinesias, which was highly reproducible. These L-DOPA-primed animals also received other D2 D1, and mixed D1/D2 agonist drugs. Quinpirole, bromocriptine, pergolide, apomorphine, and A-77636 all produce dyskinesias that were identical in character to those seen after L-DOPA administration, but the D1 agonist A-77636 gradually abolished dyskinesias while preserving its antiparkinsonian activity. The MPTP-treated marmoset provides a useful model in which to study dyskinesias in Parkinson's disease and to examine new therapeutic strategies aimed at alleviating this common side effect of chronic dopamine replacement therapy.

Authors+Show Affiliations

Neurodegenerative Diseases Research Centre, King's College London, England.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8749992

Citation

Pearce, R K., et al. "Chronic L-DOPA Administration Induces Dyskinesias in the 1-methyl-4- Phenyl-1,2,3,6-tetrahydropyridine-treated Common Marmoset (Callithrix Jacchus)." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 10, no. 6, 1995, pp. 731-40.
Pearce RK, Jackson M, Smith L, et al. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord. 1995;10(6):731-40.
Pearce, R. K., Jackson, M., Smith, L., Jenner, P., & Marsden, C. D. (1995). Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Movement Disorders : Official Journal of the Movement Disorder Society, 10(6), 731-40.
Pearce RK, et al. Chronic L-DOPA Administration Induces Dyskinesias in the 1-methyl-4- Phenyl-1,2,3,6-tetrahydropyridine-treated Common Marmoset (Callithrix Jacchus). Mov Disord. 1995;10(6):731-40. PubMed PMID: 8749992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). AU - Pearce,R K, AU - Jackson,M, AU - Smith,L, AU - Jenner,P, AU - Marsden,C D, PY - 1995/11/1/pubmed PY - 1995/11/1/medline PY - 1995/11/1/entrez SP - 731 EP - 40 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 10 IS - 6 N2 - Dyskinesias occur in the majority of patients with Parkinson's disease chronically treated with L-DOPA and also occur in several nonhuman primate species after 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) and L-DOPA treatment. The common marmoset (Callithrix jacchus) shows parkinsonian motor deficits after MPTP administration, and we now report dyskinesias occurring in this species during chronic L-DOPA exposure. Marmosets rendered chronically parkinsonian after MPTP administration were treated orally with L-DOPA plus carbidopa for 3 weeks. After several days the animals began to display chorea, choreoathetosis, and dystonia. The severity of dyskinesias varied between the animals, with the most severely parkinsonian animals displaying the most dyskinetic movements. Each animal showed an idiosyncratic pattern of dyskinesias, which was highly reproducible. These L-DOPA-primed animals also received other D2 D1, and mixed D1/D2 agonist drugs. Quinpirole, bromocriptine, pergolide, apomorphine, and A-77636 all produce dyskinesias that were identical in character to those seen after L-DOPA administration, but the D1 agonist A-77636 gradually abolished dyskinesias while preserving its antiparkinsonian activity. The MPTP-treated marmoset provides a useful model in which to study dyskinesias in Parkinson's disease and to examine new therapeutic strategies aimed at alleviating this common side effect of chronic dopamine replacement therapy. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/8749992/Chronic_L_DOPA_administration_induces_dyskinesias_in_the_1_methyl_4__phenyl_1236_tetrahydropyridine_treated_common_marmoset__Callithrix_Jacchus__ L2 - https://doi.org/10.1002/mds.870100606 DB - PRIME DP - Unbound Medicine ER -